Semler Scientific (NASDAQ:SMLR) Releases Quarterly Earnings Results, Beats Expectations By $5.31 EPS

Key Points

• Semler Scientific reported earnings of $5.04 per share, significantly exceeding expectations by $5.31 EPS, compared to the consensus estimate of ($0.27).
• The company's stock increased by 2.6%, reaching $35.37 during mid-day trading, with a current market capitalization of $487.68 million.
• Analysts have mixed ratings on Semler Scientific, with one "sell" rating and several "buy" ratings, leading to a consensus rating of "Moderate Buy" and a target price of $82.00.

Semler Scientific (NASDAQ:SMLR - Get Free Report) announced its quarterly earnings results on Monday. The company reported $5.04 EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $5.31, Zacks reports. The company had revenue of $8.22 million during the quarter, compared to analysts' expectations of $8.10 million. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.

Semler Scientific Stock Performance

Shares of SMLR traded down $1.42 during midday trading on Friday, reaching $36.13. 229,106 shares of the stock were exchanged, compared to its average volume of 691,162. Semler Scientific has a twelve month low of $21.77 and a twelve month high of $81.56. The company has a quick ratio of 0.51, a current ratio of 0.60 and a debt-to-equity ratio of 0.25. The company has a market cap of $535.01 million, a P/E ratio of 14.88 and a beta of 1.34. The stock's 50 day simple moving average is $37.51 and its 200 day simple moving average is $39.56.

Wall Street Analysts Forecast Growth

SMLR has been the subject of a number of research reports. Wall Street Zen cut Semler Scientific from a "buy" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald cut their price objective on Semler Scientific from $61.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday. Maxim Group raised Semler Scientific to a "strong-buy" rating and set a $95.00 price objective for the company in a report on Wednesday, July 9th. Finally, Benchmark began coverage on Semler Scientific in a report on Tuesday, July 8th. They issued a "buy" rating and a $101.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $81.75.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SMLR. Royal Bank of Canada boosted its stake in shares of Semler Scientific by 101.2% during the first quarter. Royal Bank of Canada now owns 43,977 shares of the company's stock valued at $1,592,000 after purchasing an additional 22,123 shares in the last quarter. AQR Capital Management LLC lifted its stake in Semler Scientific by 71.7% in the first quarter. AQR Capital Management LLC now owns 15,251 shares of the company's stock valued at $552,000 after buying an additional 6,371 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Semler Scientific by 47.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,965 shares of the company's stock valued at $144,000 after buying an additional 1,269 shares during the period. Institutional investors own 49.37% of the company's stock.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.